Vaccines

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The New Jersey Department of Health has issued a public health alert warning of another potential measles exposure at Newark International Airport.

At present, multiple vaccine candidates are in various stages of research and development, including cabotegravir, which is currently in phase 3 trials, and vaccines based on broadly-neutralizing antibodies.

As flu activity continues to decline in the United States, some states are still reporting a record number of flu illnesses, as a new study debunks concerns that the use of Tamiflu may lead to increased suicide risk in teens.

In the wake of Europe’s recent 4-fold increase in measles cases, countries such as Italy, Germany, and Romania are passing tougher laws requiring vaccinations for children being enrolled in school.

Flu activity is down for the second week in a row in the United States, but as the flu season still has several weeks to go, the FDA has issued a warning about counterfeit flu medications.

New research from Australia supports the use of booster doses of the pneumococcal conjugate vaccine, but it shows overall effectiveness is high.

Better understanding of the pathogenesis of tuberculosis can help inform the development of a new, effective vaccine.

The US Food and Drug Administration (FDA) has weighed in on the strains to be included in the 2018-2019 influenza vaccine.

The results of the trial revealed that the tablet reduced the rate of infection with influenza by 48%.

The institute has made the development of the vaccine “one of its highest priorities.”

A new bill introduced by a group of senators aims to boost universal flu vaccine research by $1 billion over the next 5 years, as health officials continue to investigate the cause of the flu shot’s low efficacy.

A panel of experts in a recent symposium discuss how dental professionals can play an integral role in increasing HPV vaccination rates and decreasing HPV-related cancer.

The CDC’s Advisory Committee on Immunization Practices has included HEPLISAV-B on its list of recommended products for use to vaccinate adults against hepatitis B.

While a new report has found that the flu vaccine has been just 36% effective this year, a recent study suggests that history of exposure to flu may, in part, be to blame.

Massive vaccination campaigns launched in Brazil and Nigeria strive to quell ongoing outbreaks.